Effective delivery to the retina is presently one of the most challenging areas in drug development in ophthalmology, due to anatomical barriers preventing entry of therapeutic substances. Intraocular injection is presently the only route of administration for large protein therapeutics, including the anti-Vascular Endothelial Growth Factors Lucentis (ranibizumab) and Avastin (bevacizumab). Anti-VEGFs have revolutionised the management of age-related macular degeneration and have increasing indications for use as sight-saving therapies in diabetes and retinal vascular disease.
As part of the assessment and development of therapeutics to RGC death which we are monitoring via the DARC Technology, our lab is developing promising drug delivery strategies for administrations of such therapeutic and diagnostic molecules.
A publication in this field is "in press" in Small currently.